tyb
Constellation Brands is one of the leading American producers of wines, spirits and beers. Net sales break down by family of products as follows:
-
beer (61.4%): Corona Extra, Corona Light, Modelo Especial, Modelo Negra, Modelo Chelada, Pacifico and Victoria brands;
-
wines (33.8%): Robert Mondavi, Simi, Mark Xest, Kim Crawford, Estancia, Clos du Bois, Black Box brands, etc.;
-
spirits 4.8%): Black Velvet, Svedka Vodka, Casa Noble and High West brands.
The United States account for 96.6% of net sales.
Number of employees : 9 600 people.
https://www.marketscreener.com/CONSTELLATION-BRANDS-14502/company/
https://www.secform4.com/insider-trading/16918.htm
POTUS to decide on $300 billion China tariffs after G20 meeting
CAEN, France (Reuters) - U.S. President Donald Trump said on Thursday he would make a decision about whether to impose a further series of tariffs on Chinese goods after meeting his Chinese counterpart at the G-20 meeting in Japan later this month.
Trump earlier threatened to hit China with tariffs on “at least” another $300 billion worth of goods, but said he thought both China and Mexico wanted to make deals in their trade disputes with the United States.
“I will make that decision I would say over the next few weeks, probably right after the G20,” Trump said ahead of talks with French President Emmanuel Macron in Normandy, where they attended a ceremony for the 75th anniversary of D-Day.
“One way or another I’ll make that decision after the G20. I’ll be meeting with President Xi (Jinping) and we will see what happens,” Trump said.
Tensions between the world’s two largest economies have risen sharply since talks aimed at ending a festering trade war broke down in early May.
While Trump said on Thursday that talks with China were ongoing, no face-to-face meetings have been held since May 10, the day he sharply increased tariffs on a $200 billion list of Chinese goods to 25%, prompting Beijing to retaliate.
https://www.reuters.com/article/us-usa-trade-china-trump/trump-to-make-china-tariffs-decision-right-after-g20-idUSKCN1T71XI
Bain Capital Life Sciences Inv sold $20m in shares of Dicerna Pharmaceuticals-May 29
Dicerna Pharmaceuticals, Inc. is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined. The Company uses its RNAi technology platform to build a pipeline in these therapeutic areas. The Company develops dacryocystorhinostomy (DCR)-Primary Hyperoxaluria Type 1 (PH1) for the treatment of PH1 by targeting the gene encoding the liver enzyme glycolate oxidase. The Company uses its dicer substrate RNA (DsiRNA)-EX Conjugate technology to develop a subcutaneously injected treatment for PH1. The Company develops DCR-MYC for the treatment of MYC-related cancers, including hepatocellular carcinoma (HCC) and pancreatic neuroendocrine tumors (PNET).
Number of employees : 44 people.
https://www.marketscreener.com/DICERNA-PHARMACEUTICALS-I-15657740/company/
https://www.secform4.com/insider-trading/1399529.htm
Rennes Foundation bought $9.9m of Xbiotech Inc.-June 4
XBiotech Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing True Human monoclonal antibodies for treating a range of different diseases. It focuses on its lead product candidate, Xilonix (MABp1), which is derived from a natural human immune response. The Company has also developed a True Human monoclonal antibody discovery platform and manufacturing system. Xilonix is a therapeutic antibody, which specifically neutralizes interleukin-1 alpha (IL-1a). Its pipeline includes various human antibodies for treating diseases, such as cancer, vascular disease, inflammatory skin disease and diabetes. The Company has completed a Phase III study in Europe for the treatment of symptomatic colorectal cancer. It also investigated its lead product candidate in clinical trials for other inflammatory conditions, including vascular disease, type II diabetes, acne, psoriasis, pyoderma gangrenosum (PG) and hidradenitis suppurativa (HS).
https://www.marketscreener.com/XBIOTECH-INC-20708500/company/
XBiotech Announces Closing of Public Offering of Common Shares
AUSTIN, Texas, June 04, 2019 (GLOBE NEWSWIRE) – XBiotech Inc. (NASDAQ: XBIT) today announced the closing of its previously announced underwritten public offering of 4,848,485 of its common shares at a public offering price of $8.25 per share. In addition, XBiotech has granted the underwriter a 30-day option to purchase up to an additional 351,515 common shares at the public offering price, less underwriting discounts and commissions.
Piper Jaffray acted as the sole underwriter in the offering.
XBiotech received gross proceeds of approximately $40 million. The proceeds of the offering, after deducting underwriting discounts and commissions and estimated offering expenses payable by XBiotech, will be used primarily to advance bermekimab Phase 2 clinical trials in Hidradenitis Suppurativa and Atopic Dermatitis, and for general corporate and working capital purposes.
The common shares are being issued and sold pursuant to an effective shelf registration statement on Form S-3 previously filed with and declared effective by the Securities and Exchange Commission.
https://www.marketscreener.com/XBIOTECH-INC-20708500/news/XBiotech-Announces-Closing-of-Public-Offering-of-Common-Shares-28705797/
https://www.secform4.com/insider-trading/1626878.htm
fuck off tiersas and take your meds
no…just fuck off